Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6593306

Title:Methods for modulation and inhibition of telomerase
Inventors:Chen, Shih-Fong; San Antonio, TX, USA
Maine, Ira; San Antonio, TX, USA
Kerwin, Sean M.; Round Rock, TX, USA
Fletcher, Terace M.; San Antonio, TX, USA
Salazar, Miquel; Austin, TX, USA
Mamiya, Blain; Austin, TX, USA
Wajima, Makoto; San Antonio, TX, USA
Windle, Bradford E.; San Antonio, TX, USA
Summary:Described herein are methods of reducing the proliferative capacity of a cell via modulation and inhibition of telomerase activity. Central to the invention is the discovery that normal human stem cells produce a regulated non-processive telomerase activity, while cancer cells produce a processive telomerase activity. Furthermore, nucleotide analogs, such as 7-deaza-2'-deoxyquanosine-5'-triphosphate (7-deaza-dGTP) were found to be substrates for processive telomerase and incorporated into telomeric sequences. Described herein are means by which the incorporation of this nucleotide subsequently affects the processivity of telomerase, converting processive telomerase to non-processive telomerase, and inhibiting the formation of G-quartets by telomeric sequence. Further disclosed are methods for converting cancer processive telomerase to the more benign non-processive telomerase, such as by partially cleaving the telomerase RNA. Claims of the invention include nucleoside analogs which were found to be capable of a variety of activities including the mediation of allosteric-like inhibition of telomerase, premature termination and shortening of telomeric DNA, destabilization of telomeric structure and function and eventually cell death. Therapeutic applications in the treatment of cancer are included.
Abstract:It was found that normal human stem cells produce a regulated non-processive telomerase activity, while cancer cells produce a processive telomerase activity. Nucleotide analogs, such as 7-deaza-2'-deoxyquanosine-5'-triphosphate (7-deaza-dGTP) were found to be substrates for processive telomerase and incorporated into telomeric sequence. The incorporation of this nucleotide subsequently affected the processivity of telomerase, converting processive telomerase to non-processive telomerase. The incorporation of this nucleotide analogs was also found to inhibit formation of G-quartets by telomeric sequence. Other methods for converting cancer processive telomerase to the more benign non-processive telomerase include partially cleaving the telomerase RNA. The nucleoside analogs were found to be capable of a variety of activities including mediating allosteric-like inhibition of telomerase, premature termination and shortening of telomeric DNA, destabilization of telomeric structure and function and eventually cell death. Understanding the mechanisms of telomerase modulation by the 7-deaza-nucleotides has allowed the design of new telomerase inhibitors, modulators and agents for affecting telomere structure and function. These discoveries have application in the treatment of cancer.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6593306
Application Number:US1999000467932
Date Filed:21/12/1999
Date Published:15/07/2003
Assignee:Board of Regents, The University of Texas System, Austin, TX, USA CTRC Research Foundation, San Antonio, TX, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/23/2021